A clinical trial to study the role of metformin in prevention of steroid induced high blood sugars

Not Applicable

• Registration Number: CTRI/2020/09/028035
• Lead Sponsor: JIPMER

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1)Non-diabetic, steroid-naive patients or receiving a dose of less than or equal to 5 mg prednisolone equivalent per day and being started on oral glucocorticoids of more than or equal to 20 mg prednisolone or an equivalent dose of another glucocorticoid per day

2)Planned maintenance dose of glucocorticoids after tapering will be more than or equal to 7.5 mg prednisolone or an equivalent dose of other

glucocorticoid per day for at least 12 weeks

Exclusion Criteria

1)Preexisting diabetes mellitus

2)Patients receiving intravenous glucocorticoids

3)Renal insufficiency(estimated glomerular filtration rate less than 60ml/min/1.73m2)

4) Deranged liver function tests (Alanine transaminase and aspartate transaminase more than 2.5 times upper limit of normal)

5) Any chronic illness like chronic infection, chronic heart failure, malignancy, etc.

6) Pregnancy and lactation

7) Current alcohol intake of more than 20g per day for males and more than 10g per day for females or substance use

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The proportion of patients dysglycemiaTimepoint: baseline and three months

Secondary Outcome Measures

Name	Time	Method
Area under curve blood glucoseTimepoint: baseline and three months;Body compositionTimepoint: baseline and three months;Homeostatic model assessment(HOMA) indicesTimepoint: baseline and three months;Lipid profileTimepoint: baseline and three months